Tags: Drug.

Osanetant (SR-142801) was a neurokinin 3 receptor antagonist developed by Sanofi-Synthélabo which was being researched for the treatment of schizophrenia but was discontinued. It was the first non-peptide NK3 antagonist developed in the mid-1990s Other potential applications for osanetant is in the treatment of drug addiction as it has been found to block the effects of cocaine in animal models.

Osanetant.png
ATC prefix
none
CAS number
160492-56-8
FDA UNII code
K7G81N94DT
IUPAC name
N-(1-3-[(3R)-1-benzoyl-3-(34-dichlorophenyl)piperidin-3-yl]propyl-4-phenylpiperidin-4-yl]-N-methylacetamide
PubChem
219077

Loading...

This page contains content from the copyrighted Wikipedia article "Osanetant"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.